International journal of molecular sciences · 2024
A Rare Case of TP63-Associated Lymphopenia Revealed by Newborn Screening Using TREC.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marakhonov Andrey, Serebryakova Elena, Mukhina Anna, Vechkasova Anastasia, Prokhorov Nikolai, Efimova Irina, Balinova Natalia, Lobenskaya Anastasia, Vasilyeva Tatyana, Zabnenkova Victoria, Ryzhkova Oxana, Rodina Yulia, Pershin Dmitry, Soloveva Nadezhda, Fomenko Anna, Saydaeva Djamila, Ibisheva Aset, Irbaieva Taisiya, Koroteev Alexander, Zinchenko Rena, Voronin Sergey, Shcherbina Anna, Kutsev Sergey
Аннотация
The expanded newborn screening (NBS) program in the Russian Federation was initiated in 2023, among which severe combined immunodeficiency (SCID) is screened using TREC/KREC assays. Here, we report a rare case of a TP63-associated disease identified through this NBS program. Dried blood spots from newborns were initially screened for TREC/KREC levels, and those with values below the cut-off underwent confirmatory testing and further genetic analysis, including whole-exome sequencing (WES). A male newborn was identified with significantly reduced TREC values, indicative of T cell lymphopenia. Genetic analysis revealed a heterozygous NM_003722.5:c.1027C>T variant in TP63, leading to the p.(Arg343Trp) substitution within the DNA binding domain. This mutation has been previously associated with Ectrodactyly-Ectodermal Dysplasia-Cleft lip/palate syndrome (EEC) syndrome and shown to reduce the transactivation activity of TP63 in a dominant-negative manner. This case represents one of the few instances of immune system involvement in a patient with a TP63 mutation, highlighting the need for further investigation into the immunological aspects of TP63-associated disorders. Our findings suggest that comprehensive immunological evaluation should be considered for patients with TP63 mutations to better understand and manage potential immune dysfunctions.